PAPER Klinger D, Hill BL, Barda N, Halperin E, Gofrit ON, Greenblatt CL, Rappoport N, Linial M, Bercovier H

Bladder Cancer Immunotherapy by BCG Is Associated with a Significantly Reduced Risk of Alzheimer's Disease and Parkinson's Disease.

Vaccines (Basel). 2021 May 11;9(5) PubMed.

PAPER Itzhaki RF

Overwhelming Evidence for a Major Role for Herpes Simplex Virus Type 1 (HSV1) in Alzheimer's Disease (AD); Underwhelming Evidence against.

Vaccines (Basel). 2021 Jun 21;9(6) PubMed.

PAPER Chemparthy DT, Kannan M, Gordon L, Buch S, Sil S

Alzheimer's-Like Pathology at the Crossroads of HIV-Associated Neurological Disorders.

Vaccines (Basel). 2021 Aug 21;9(8) PubMed.

PAPER Vassilakopoulou V, Karachaliou CE, Evangelou A, Zikos C, Livaniou E

Peptide-Based Vaccines for Neurodegenerative Diseases: Recent Endeavors and Future Perspectives.

Vaccines (Basel). 2021 Nov 4;9(11) PubMed.

PAPER Schmidhuber S, Scheiblhofer S, Weiss R, Cserepes M, Tóvári J, Gadermaier G, Bezard E, De Giorgi F, Ichas F, Strunk D, Mandler M

A Novel C-Type Lectin Receptor-Targeted α-Synuclein-Based Parkinson Vaccine Induces Potent Immune Responses and Therapeutic Efficacy in Mice.

Vaccines (Basel). 2022 Aug 30;10(9) PubMed.

PAPER Valiukas Z, Ephraim R, Tangalakis K, Davidson M, Apostolopoulos V, Feehan J

Immunotherapies for Alzheimer's Disease-A Review.

Vaccines (Basel). 2022 Sep 14;10(9) PubMed.

PAPER Vicidomini C, Borbone N, Roviello V, Roviello GN, Oliviero G

Summary of the Current Status of DNA Vaccination for Alzheimer Disease.

Vaccines (Basel). 2023 Nov 10;11(11) PubMed.

PAPER Park JS, Ahmad R, Choe K, Kang MH, Park TJ, Kim MO

Immunization Effects of a Novel α-Synuclein-Based Peptide Epitope Vaccine in Parkinson's Disease-Associated Pathology.

Vaccines (Basel). 2023 Dec 5;11(12) PubMed.

PAPER Hovakimyan A, Chilingaryan G, King O, Capocchi JK, Chadarevian JP, Davtyan H, Kniazev R, Agadjanyan MG, Ghochikyan A

mRNA Vaccine for Alzheimer's Disease: Pilot Study.

Vaccines (Basel). 2024 Jun 14;12(6) PubMed.

PAPER Vroom MM, Dodart JC

Active Immunotherapy for the Prevention of Alzheimer's and Parkinson's Disease.

Vaccines (Basel). 2024 Aug 28;12(9) PubMed.

PAPER Kulasingam SL, Samsa GP, Zarin DA, Rutschmann OT, Patwardhan MB, McCrory DC, Schmechel DE, Matchar DB

When should functional neuroimaging techniques be used in the diagnosis and management of Alzheimer's dementia? A decision analysis.

Value Health. 2003 Sep-Oct;6(5):542-50. PubMed.

PAPER Miller EA, Schneider LS, Zbrozek A, Rosenheck RA

Sociodemographic and clinical correlates of utility scores in Alzheimer's disease.

Value Health. 2008 Dec;11(7):1120-30. PubMed.

PAPER Chung S, Mehta K, Shumway M, Alvidrez J, Perez-Stable EJ

Risk perception and preference for prevention of Alzheimer's disease.

Value Health. 2009 Jun;12(4):450-8. PubMed.

PAPER Suh GH

Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea.

Value Health. 2009 Nov-Dec;12 Suppl 3:S49-54. PubMed.

PAPER Green C, Shearer J, Ritchie CW, Zajicek JP

Model-based economic evaluation in Alzheimer's disease: a review of the methods available to model Alzheimer's disease progression.

Value Health. 2011 Jul-Aug;14(5):621-30. PubMed.